Hepatic decompensation associated with an interferon-free antiviral therapy in patients with HCV-cirrhosis
- Authors: Batskikh SN1, Vinnitskaya EV1, Sandler Y.G1, Khaimenova TY.1
-
Affiliations:
- A.S. Loginov Moscow Clinical Scientific and Practical Center, Moscow City Department of Health
- Issue: Vol 90, No 11 (2018)
- Pages: 67-73
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/32898
- DOI: https://doi.org/10.26442/terarkh201890114-73
- ID: 32898
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
S N Batskikh
A.S. Loginov Moscow Clinical Scientific and Practical Center, Moscow City Department of Health
Email: zdoc@mail.ru
к.м.н., с.н.с. отдела гепатологии ГБУЗ «МКНЦ им. А.С. Логинова» ДЗМ; н.с. ФБУН «Центральный НИИ эпидемиологии» Роспотребнадзора; ORCID iD 0000-0002-5917-203X Moscow, Russia
E V Vinnitskaya
A.S. Loginov Moscow Clinical Scientific and Practical Center, Moscow City Department of Healthд.м.н., зав. отделом гепатологии Moscow, Russia
Yu G Sandler
A.S. Loginov Moscow Clinical Scientific and Practical Center, Moscow City Department of Healthк.м.н., с.н.с. научно-исследовательского отдела гепатологии Moscow, Russia
T Yu Khaimenova
A.S. Loginov Moscow Clinical Scientific and Practical Center, Moscow City Department of Healthк.м.н., зав. отд-нием хронических заболеваний печени Moscow, Russia
References
- Jessica K. Dyson, John Hutchinson, Laura Harrison, Olorunda Rotimi, Dina Tiniakos, Graham R. Foster, Mark A. Aldersley, Stuart Mc Pherson. Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. J Hepatology. 2016;64:234-8. https://doi.org/10.1016/ j.jhep.2015.07.041
- Jonathan G. Stine, Nicolas Intagliata, Neeral L. Shah, Curtis K. Argo, Stephen H. Caldwell, James H. Lewis, Patrick G. Northup. Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis. Digestive Disease and Sciences. 2015;60:1031-5. https://doi.org/10.1007/s10620-014-3422-x
- Martin-Walter Welker, Stefan Luhne, Christian M. Lange, Johannes Vermehren, Harald Farnik, Eva Herrmann, Tania Welzel, Stefan Zeuzem, Christoph Sarrazin. Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/ sofosbuvir treatment. J Hepatology. 2016;64:790-9. https://doi.org/10.1016/j.jhep.2015.11.034
- Fred Poordad, David R. Nelson, Jordan J. Feld, Michael W. Fried, Heiner Wedemeyer, Lois Larsen, Daniel E. Cohen, Eric Cohen, Niloufar Mobashery, Fernando Tatsch, Graham R. Foster. Safety of the 2D/3D direct - acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysis. J Hepatology. 2017;67:700-7. https://doi.org/10.1016/j.jhep.2017.06.011
- Bart J. Veldt, E. Jenny Heathcote, Heiner Wedemeyer, Juerg Reichen, W. Peter Hofmann, Stefan Zeuzem, Michael P. Manns, Bettina E. Hansen, Solko W. Schalm, Harry L.A. Janssen. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147(10):677-84. https://doi.org/10.7326/0003-4819-147-10-200711200-00003
- Adriaan J. van der Meer, Bart J. Veldt, Jordan J. Feld, Heiner Wedemeyer, Jean-François Dufour, Frank Lammert, Andres Duarte-Rojo, E. Jenny Heathcote, Michael P. Manns, Lorenz Kuske, Stefan Zeuzem, W. Peter Hofmann, Robert J. de Knegt, Bettina E. Hansen, Harry L. A. Janssen. Association between sustained virological response and all - cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584-93. https://doi.org/ 10.1001/jama.2012.144878
- Rebecca L. Morgan, Brittney Baack, Bryce D. Smith, Anthony Yartel, Marc Pitasi, Yngve Falck-Ytter. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta - analysis of observational studies. Ann Intern Med. 2013;158(5 Pt 1):329-37. https://doi.org/10.7326/0003-4819-158-5-201303050-00005
- Heiner Wedemeyer, Jens Reimer, Petra Sandow, Dietrich Hueppe, Thomas Lutz, Kurt Gruengreiff, Joerg Goelz, Stefan Christensen, Heike Pfeiffer-Vornkahl, UlrichAlshuth, Michael P. Mann. Long - term Outcome of Chronic Hepatitis C (CHC) Virus Infection in a Real-World Setting: The German LOTOS Study. Liver International. 2017;37:1468-75. https://doi.org/10.1111/liv.13399
- Jay H. Hoofnagle. Hepatic decompensation during direct - acting antiviral therapy of chronic hepatitis C. J Hepatology. 2016;646:763-5. https://doi.org/10.1016/j.jhep.2016.01.007
- Welker M.W, Luhne S, Lange C.M, Farnik H, Herrmann E, Welzel T, Zeuzem S, Christoph S. Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/ sofosbuvir treatment. J Hepatology. 2016;64:790-9. https://doi.org/10.1016/j.jhep.2015.11.034
- Scheiner B, Lindner G, Reiberger T, Schneeweiss B, Trauner M, Zauner C, Funk G.C. Acid - base disorders in liver disease. J Hepatology. 2017;67:1062-73. https://doi.org/10.1016/j.jhep.2017.06.023
- Vanwolleghem T, Meuleman P, Libbrecht L, Roskams T, De Vos R, Leroux-Roels G. Ultra-Rapid Cardiotoxicity of the Hepatitis C Virus Protease Inhibitor BILN 2061 in the Urokinase-Type Plasminogen Activator Mouse. Gastroenterology. 2007;133(4):1144-55. https://doi.org/ 10.1053/j.gastro.2007.07.007
- Sheridan C. Calamitous HCV trial casts shadow over nucleoside drugs. Nature Biotechnology. 2012;30:1015-6. https://doi.org/10.1038/ nbt1112-1015
- Arnold J.J, Sharma S.D, Feng J.Y, Ray A.S, Smidansky E.D, Kireeva M.L, Cho A, Perry J, Vela J.E, Park Y, Xu Y, Tian Y, Babusis D, Barauskus O, Peterson B.R, Gnatt A, Kashlev M, Zhong W, Cameron C.E. Sensitivity of Mitochondrial Transcription and Resistance of RNA Polymerase II Dependant Nuclear Transcription to Antiviral Ribonucleosides. PLoS Pathogens. 2012;8(11):e1003030. https://doi.org/10.1371/ journal.ppat.1003030
- Mc Kenzie R, Fried M.W, Sallie R, Conjeevaram H, Di Bisceglie A.M, Park Y, Savarese B, Kleiner D, Tsokos M, Luciano C, Pruett T, Stotka J.L, Straus S.E, Hoofnagle.JH. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med. 1995;333:1099-105. https://doi.org/10.1056/nejm199510263331702
- Tujios S, Fontana R.J. Mechanisms of drug - induced liver injury: from bedside to bench. Nature Reviews Gastroenterology & Hepatology. 2011 Apr;8(4):202-11. https://doi.org/10.1038/nrgastro.2011.22
- Xu D, Nishimura T, Nishimura S, Zhang H, Zheng M, Guo Y.Y, Masek M, Michie S.A, Glenn J, Peltz G. Fialuridine induces acute liver failure in chimeric TK-NOG mice:a model for detecting hepatic drug toxicity prior to human testing. PLoS Med. 2014;11:31001628. https://doi.org/10.1371/journal.pmed.1001628
- Coats S.J, Garnier-Amblard E.C, Amblard F, Ehteshami M, Amiralaei S, Zhang H, Zhou L, Boucle S.R.L, Lu X, Bondada L, Shelton J.R, Li H, Liu P, Li C, Cho J.H, Chavre S.N, Zhou S, Mathew J, Schinazi R.F. Chutes and ladders in hepatitis C nucleoside drug development. Antiviral Res. 2014;102:119-47. https://doi.org/10.1016/ j.antiviral.2013.11.008
- Renet S, Chaumais M.C, Antonini T, Zhao A, Thomas L, Savoure A, Samuel D, Duclos-Vallée J.C, Algalarrondo V. Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge. Gastroenterology. 2015;149(6):1378-80. https://doi.org/10.1053/j.gastro.2015.07.051
- EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatology. 2017;66:153-94. https://doi.org/10.1016/j.jhep.2016.09.001
- AASLD/IDSA HCV Guidance Panel Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;4(62)3:932-54. https://doi.org/10.1002/hep.27950
- Dufour J.H, Dziejman M, Liu M.T, Leung J.H, Lane T.E, Luster A.D. IFN-gamma - inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in eff ector T cell generation and trafficking. J Immunol. 2002;168:3195-204. https://doi.org/10.4049/ jimmunol.168.7.3195
- Edward J Gane, Stuart K Roberts, Catherine A.M Stedman, Peter W Angus, Brett Ritchie, Rob Elston, David Ipe, Peter N Morcos, Linda Baher, Isabel Najera, Tom Chu, Uri Lopatin, M Michelle Berrey, William Bradford, Mark Laughlin, Nancy S Shulman, Patrick F Smith. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double - blind, placebo - controlled, dose - escalation trial. Lancet. 2010;376:1467-75. https://doi.org/10.1016/ s0140-6736(10)61384-0
- Meike H. van der Ree, Femke Stelma, Sophie B. Willemse, Anthony Brown, Leo Swadling, Marc van der Valk, Marjan J. Sinnige, Ad C. van Nuenen, J. Marleen L. de Vree, Paul Klenerman, Eleanor Barnes, Neeltje A. Kootstra, Hendrik W. Reesink. Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing. Antiviral Research. 2017;146:139-45. https://doi.org/10.1016 j.antiviral.2017.08.016
- Eric G. Meissner, David Wu, Anu Osinusi, Dimitra Bon, Kimmo Virtaneva, Dan Sturdevant, Steve Porcella, Honghui Wang, Eva Herrmann, John Mc Hutchison, Anthony F. Suffredini, Michael Polis, Stephen Hewitt, Ludmila Prokunina-Olsson, Henry Masur, Anthony S. Fauci, Shyamasundaran Kottilil. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clinical. 2014;124:3352-63. https://doi.org/10.1172/jci75938
- Jens M. Werner, Akinbami Adenugba, Ulrike Protzer. Immune Reconstitution After HCV Clearance With Direct Antiviral Agents: Potential Consequences for Patients With HCC? Transplantation. 2017;101(5):904-9. https://doi.org/10.1097/tp.0000000000001606
- Oldford S.A, Arseneault K, Barrett L. Early Immune Changes during HCV DAA Therapy in an Incarcerated Population. J Hepatology. 2016;64:525-26. https://doi.org/10.1016/s0168-8278(16)00926-0
![](/img/style/loading.gif)